Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2217685 | 0.71 | — | — | |
| SCHEMBL6978501 | 0.69 | — | — | |
| SCHEMBL155319 | 0.68 | NOS1 (0.36) | NOS1 | |
| SCHEMBL577762 | 0.68 | NOS1 (0.36) | NOS1 | |
| SCHEMBL2152817 | 0.67 | PDK1 (0.43) | ALDH1A1 | |
| SCHEMBL28941188 | 0.67 | PDK1 (0.43) | ALDH1A1 | |
| SCHEMBL226631 | 0.67 | FBP1 (0.46) | ALDH1A1GAA | |
| SCHEMBL25269699 | 0.65 | — | — | |
| SCHEMBL3322195 | 0.63 | — | — | |
| SCHEMBL28716150 | 0.63 | KAT2B (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023056589-A1 | MENIN INHIBITORS AND METHODS OF USE FOR TREATING CANCER | SERVIER PHARMACEUTICALS LLC (US) | 2023-04-13 | — | — | WO | disclosed |
| US-20170137407-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. | 2017-05-18 | — | — | US | disclosed |
| US-9546180-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2017-01-17 | — | — | US | disclosed |
| US-9353100-B2 | Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections | IDENIX PHARMACEUTICALS LLC (US) | 2016-05-31 | — | — | US | disclosed |
| EP-2461811-B1 | MACROCYCLIC SERINE PROTEASE INHIBITORS USEFUL AGAINST VIRAL INFECTIONS, PARTICULARLY HCV | IDENIX PHARMACEUTICALS LLC (US) | 2016-04-20 | — | — | EP | disclosed |
| US-9284307-B2 | Macrocyclic serine protease inhibitors | IDENIX PHARMACEUTICALS LLC (US) | 2016-03-15 | — | — | US | disclosed |
| US-20160045505-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS AG (CH) | 2016-02-18 | — | — | US | disclosed |
| EP-2970324-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | Novartis AG (CH) | 2016-01-20 | — | — | EP | disclosed |
| US-9115141-B2 | Substituted isoquinolinones and methods of treatment thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2015-08-25 | — | — | US | disclosed |
| US-8993595-B2 | Macrocyclic serine protease inhibitors | IDENIX PHARMACEUTICALS, INC. (US) | 2015-03-31 | — | — | US | disclosed |
| WO-2011017389-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS USEFUL AGAINST VIRAL INFECTIONS, PARTICULARLY HCV | IDENIX PHARMACEUTICALS, INC. (US) | 2011-02-10 | — | — | WO | disclosed |
| WO-2010118078-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | IDENIX PHARMACEUTICALS, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
| US-20100260710-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | IDENIX PHARMACEUTICALS, INC. (US) | 2010-10-14 | — | — | US | disclosed |
| WO-2010065383-A1 | CALCILYTIC COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2010-06-10 | — | — | WO | disclosed |
| US-20100069358-A1 | USE OF 7-AZAINDOLES IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-03-18 | — | — | US | disclosed |
| EP-2125801-A1 | THE USE OF 7-AZAINDOLES IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | Eisai R&D Management Co., Ltd. (JP) | 2009-12-02 | — | — | EP | disclosed |
| US-20090137557-A1 | Calcilytic Compounds | SMITHKLINE BEECHAM CORPORATION | 2009-05-28 | — | — | US | disclosed |
| WO-2008095943-A1 | THE USE OF 7-AZAINDOLES IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | EISAI R&D MANAGEMENT CO. LTD. (JP) | 2008-08-14 | — | — | WO | disclosed |
| EP-1951244-A2 | CALCILYTIC COMPOUNDS | SmithKline Beecham Corporation (US) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007062370-A2 | CALCILYTIC COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170137407-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | AKT3, PIK3CA, AKT1 | NOS1 2919/4885ALDH1A1 3879/4885GAA 557/4885 |
| US-20160045505-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | TYR, TUBA1C, TBCA | NOS1 566/4885ALDH1A1 482/4885GAA 30/4885 |
| US-20090137557-A1 | Calcilytic Compounds | CALCR, SOST, CALCB | NOS1 4485/4885ALDH1A1 4674/4885GAA 399/4885 |
| US-20100260710-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | SERPINB1, SPINT2, PRSS1 | NOS1 3504/4885ALDH1A1 1913/4885GAA 388/4885 |
| US-20100069358-A1 | USE OF 7-AZAINDOLES IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | MAPK7, MAPKAPK5, MAPK13 | NOS1 753/4885ALDH1A1 2520/4885GAA 2638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.